Occam Places Chau Cheng as VP of Investor Relations & Corporate Communications at Cytomx
CytomX is a public, clinical-stage, oncology-focused biopharmaceutical company developing antibody drug conjugates. By pioneering a novel class of conditionally activated biologics, powered by its Probody® technology platform, CytomX’s goal is to transcend the limits of current cancer treatments by successfully leveraging therapeutic targets that were once thought to be inaccessible.
In early 2021, Occam recruited Chau Cheng, PhD as VP, Investor Relations & Corporate Communications. Previously, Chau led investor relations at Immunomedics, Inc. for over 15 years until the company’s acquisition by Gilead Sciences for $21B.
Related Placements
Occam Global is an international life science executive search and leadership advisory firm dedicated to building management teams for innovative companies in the biotech, techbio, life sciences, and venture capital sectors. Our firm’s unique strength lies in our seamless access to elite talent, proven expertise in aligning exceptional business and scientific leaders with optimal opportunities, and a steadfast dedication to creating meaningful industry impact, guided by elevated ethics and enlightened aggression. Trusted by entrepreneurs, investors, and corporations worldwide, Occam Global is recognized as the premier partner for executive search and recruitment in the life sciences. Our success is rooted in establishing trust, cultivating and valuing relationships, and committing to serve as forthright and good-humored partners in realizing extraordinary ambitions.